Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica)

Francesca Fioredda, Michaela Calvillo, Sonia Bonanomi, Tiziana Coliva, Fabio Tucci, Piero Farruggia, Marta Pillon, Baldassarre Martire, Roberta Ghilardi, Ugo Ramenghi, Daniela Renga, Giuseppe Menna, Anna Pusiol, Angelica Barone, Eleonora Gambineri, Giovanni Palazzi, Gabriella Casazza, Marina Lanciotti, Carlo Dufour

Research output: Contribution to journalArticle

Abstract

The management of congenital and acquired neutropenias presents some differences according to the type of the disease. Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is not standardized and scanty data are available on the best schedule to apply. The frequency and the type of longitudinal controls in patients affected with neutropenias are not usually discussed in the literature. The Neutropenia Committee of the Marrow Failure Syndrome Group (MFSG) of the Associazione Italiana di Emato-Oncologia Pediatrica (AIEOP) elaborated this document following design and methodology formerly approved by the AIEOP board. The panel of experts reviewed the literature on the topic and participated in a conference producing a document that includes recommendations on neutropenia treatment and timing of follow-up.

Original languageEnglish
Pages (from-to)238-243
Number of pages6
JournalAmerican Journal of Hematology
Volume87
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Neutropenia
Bone Marrow
Guidelines
Granulocyte Colony-Stimulating Factor
Appointments and Schedules
Therapeutics
Neutropenia, Severe Congenital, Autosomal Recessive 3

ASJC Scopus subject areas

  • Hematology

Cite this

Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica). / Fioredda, Francesca; Calvillo, Michaela; Bonanomi, Sonia; Coliva, Tiziana; Tucci, Fabio; Farruggia, Piero; Pillon, Marta; Martire, Baldassarre; Ghilardi, Roberta; Ramenghi, Ugo; Renga, Daniela; Menna, Giuseppe; Pusiol, Anna; Barone, Angelica; Gambineri, Eleonora; Palazzi, Giovanni; Casazza, Gabriella; Lanciotti, Marina; Dufour, Carlo.

In: American Journal of Hematology, Vol. 87, No. 2, 02.2012, p. 238-243.

Research output: Contribution to journalArticle

Fioredda, Francesca ; Calvillo, Michaela ; Bonanomi, Sonia ; Coliva, Tiziana ; Tucci, Fabio ; Farruggia, Piero ; Pillon, Marta ; Martire, Baldassarre ; Ghilardi, Roberta ; Ramenghi, Ugo ; Renga, Daniela ; Menna, Giuseppe ; Pusiol, Anna ; Barone, Angelica ; Gambineri, Eleonora ; Palazzi, Giovanni ; Casazza, Gabriella ; Lanciotti, Marina ; Dufour, Carlo. / Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica). In: American Journal of Hematology. 2012 ; Vol. 87, No. 2. pp. 238-243.
@article{b588ea8b602d4f9baad065ddc9ab7afc,
title = "Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica)",
abstract = "The management of congenital and acquired neutropenias presents some differences according to the type of the disease. Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is not standardized and scanty data are available on the best schedule to apply. The frequency and the type of longitudinal controls in patients affected with neutropenias are not usually discussed in the literature. The Neutropenia Committee of the Marrow Failure Syndrome Group (MFSG) of the Associazione Italiana di Emato-Oncologia Pediatrica (AIEOP) elaborated this document following design and methodology formerly approved by the AIEOP board. The panel of experts reviewed the literature on the topic and participated in a conference producing a document that includes recommendations on neutropenia treatment and timing of follow-up.",
author = "Francesca Fioredda and Michaela Calvillo and Sonia Bonanomi and Tiziana Coliva and Fabio Tucci and Piero Farruggia and Marta Pillon and Baldassarre Martire and Roberta Ghilardi and Ugo Ramenghi and Daniela Renga and Giuseppe Menna and Anna Pusiol and Angelica Barone and Eleonora Gambineri and Giovanni Palazzi and Gabriella Casazza and Marina Lanciotti and Carlo Dufour",
year = "2012",
month = "2",
doi = "10.1002/ajh.22242",
language = "English",
volume = "87",
pages = "238--243",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica)

AU - Fioredda, Francesca

AU - Calvillo, Michaela

AU - Bonanomi, Sonia

AU - Coliva, Tiziana

AU - Tucci, Fabio

AU - Farruggia, Piero

AU - Pillon, Marta

AU - Martire, Baldassarre

AU - Ghilardi, Roberta

AU - Ramenghi, Ugo

AU - Renga, Daniela

AU - Menna, Giuseppe

AU - Pusiol, Anna

AU - Barone, Angelica

AU - Gambineri, Eleonora

AU - Palazzi, Giovanni

AU - Casazza, Gabriella

AU - Lanciotti, Marina

AU - Dufour, Carlo

PY - 2012/2

Y1 - 2012/2

N2 - The management of congenital and acquired neutropenias presents some differences according to the type of the disease. Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is not standardized and scanty data are available on the best schedule to apply. The frequency and the type of longitudinal controls in patients affected with neutropenias are not usually discussed in the literature. The Neutropenia Committee of the Marrow Failure Syndrome Group (MFSG) of the Associazione Italiana di Emato-Oncologia Pediatrica (AIEOP) elaborated this document following design and methodology formerly approved by the AIEOP board. The panel of experts reviewed the literature on the topic and participated in a conference producing a document that includes recommendations on neutropenia treatment and timing of follow-up.

AB - The management of congenital and acquired neutropenias presents some differences according to the type of the disease. Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is not standardized and scanty data are available on the best schedule to apply. The frequency and the type of longitudinal controls in patients affected with neutropenias are not usually discussed in the literature. The Neutropenia Committee of the Marrow Failure Syndrome Group (MFSG) of the Associazione Italiana di Emato-Oncologia Pediatrica (AIEOP) elaborated this document following design and methodology formerly approved by the AIEOP board. The panel of experts reviewed the literature on the topic and participated in a conference producing a document that includes recommendations on neutropenia treatment and timing of follow-up.

UR - http://www.scopus.com/inward/record.url?scp=84855951235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855951235&partnerID=8YFLogxK

U2 - 10.1002/ajh.22242

DO - 10.1002/ajh.22242

M3 - Article

C2 - 22213173

AN - SCOPUS:84855951235

VL - 87

SP - 238

EP - 243

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -